Gilead Sciences, Inc. achieved a 10% revenue growth in Q2 2026, totaling $7.8 billion, surpassing expectations with a non-GAAP diluted loss per share of $6.75. This progress, particularly supported by its HIV portfolio, indicates strong operational momentum, important for ongoing investor confidence.
Key Highlights
- Gilead Sciences, Inc. reported second quarter 2026 revenues of $7.8 billion, marking a 10% increase compared to the previous year.
- Total product sales for the second quarter rose 8% to $7.6 billion.
- Gilead's diluted loss per share hit $-8.45, a stark contrast to $1.56 in Q2 2025, largely driven by $9.08 per share in costs related to acquired in-process research and development (IPR&D).
Gilead Sciences, Inc. reported second quarter 2026 revenues of $7.8 billion, marking a 10% increase compared to the previous year. This performance was boosted by substantial growth in its HIV product sales and a solid increase in royalties and contracts. The consistent revenue trajectory strengthens investor confidence, particularly in light of Gilead's strategic focus on HIV therapies and oncology.
Revenue Growth Driven by HIV Portfolio
Total product sales for the second quarter rose 8% to $7.6 billion. Excluding the decline in Veklury sales, product sales increased by 10%. This growth was mainly attributed to the strong performance of Gilead’s HIV portfolio, which saw sales leap 12% to $5.7 billion.
The prominent player in this segment, Biktarvy, reported $3.8 billion in sales, a 7% increase year-over-year. Higher demand across HIV products underscores the effectiveness of Gilead’s strategies to expand its market share in this segment, important for maintaining competitive advantage.
Financial Mechanics and Strategic Investments
Gilead's diluted loss per share hit $-8.45, a stark contrast to $1.56 in Q2 2025, largely driven by $9.08 per share in costs related to acquired in-process research and development (IPR&D). The company expended approximately $11.2 billion for IPR&D tied to recent acquisitions, impacting profitability despite increased revenues. Nonetheless, Gilead's operating cash flow remained strong at $3.6 billion, and the total cash on hand is currently $3.2 billion, showcasing its strong liquidity amid ongoing investment in innovation.
Why Now? Market Position and Forward Guidance
The market has reacted positively to Gilead's Q2 results, as evidenced by an 11.2% gain in shares year-to-date. Gilead's updated guidance for full-year product sales has been raised to a range of $30.1 billion to $30.4 billion, endorsing its growth trajectory and reflecting increased confidence in its product pipeline. As Gilead moves forward, the upcoming FDA decisions on new HIV treatments set for February 2, 2027, could serve as significant market catalysts.
Peers Moving on This News
- AbbVie Inc (ABBV) up 0.3%
- Amgen Inc (AMGN) up 0.2%
- Vertex Pharmaceuticals Inc (VRTX) up 0.5%
Analysis based on the Form 8-K filed 4 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...